好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Impact of Statin Use on the Risk of Diabetic Polyneuropathy in Patients with Type 2 Diabetes and Hypercholesterolemia: A Multicenter Global Retrospective Cohort Study
General Neurology
P6 - Poster Session 6 (11:45 AM-12:45 PM)
11-011

This study aims to investigate the association of statin use with the development of diabetic polyneuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and hypercholesterolemia.

The relationship between statin use and the risk of DPN in patients with type T2DM remains a subject of considerable clinical interest. 

We conducted a retrospective cohort study utilizing the TriNetX database. Two cohorts were compared: the DMHyperco cohort, comprising patients with T2DM and hypercholesterolemia, and the DMHyperco+S cohort, comprising patients with T2DM, hypercholesterolemia, and statin use. Propensity score matching was applied to balance the cohorts based on demographics (age and sex) and clinical parameters (glucose, HbA1c, BMI, and blood pressure).
Our study included 2,264,122 patients in the DMHyperco cohort and 972,929 patients in the DMHyperco+S cohort. After propensity score matching by demographics and laboratory values, the incidence of DPN was observed in 34,344 (3.7%) patients in the DMHyperco cohort and 50,705 patients (5.6) in the DMHyperco+S cohort. Statistical analysis revealed a significant association between statin use and the incidence of DPN, with a risk ratio of 1.501 (95% CI: 1.481, 1.521). This indicates that statin use is associated with a greater risk of developing DPN.
 Our findings suggest that statin use in patients with T2DM and hypercholesterolemia is significantly associated with an increased risk of developing diabetic polyneuropathy. This risk highlights the need for careful consideration and monitoring of statin therapy in the management of patients with T2DM. Further research is warranted to elucidate the underlying mechanisms and to explore potential strategies to mitigate this risk.
Authors/Disclosures
Filipi F. Andreão
PRESENTER 		Mr. Andreão has nothing to disclose.
Filipe V. Ribeiro, MD Ms. Ribeiro has nothing to disclose.
Murilo D. Mancilha, Student Mr. Mancilha has nothing to disclose.
Gabriel L. Cunha, Medical Student Mr. Cunha has nothing to disclose.
Davi N. Coelho Mr. Coelho has nothing to disclose.
Matheus D. Pereira, MD Dr. Pereira has nothing to disclose.
Savio Batista, MD (Emory University) Mr. Batista has nothing to disclose.
Carolina B. Moura, MD (Hospital Universitário Antonio Pedro) Dr. Moura has nothing to disclose.
Diogo Haddad Santos, MD (Moema) Dr. Haddad Santos has nothing to disclose.